Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Upcoming Result Date: May 15, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
DOLPHMED (DOLPHMED) is currently trading at N/A per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Dolphin Medical Services Limited, founded in 1992, specializes in comprehensive diagnostic services, including radiology, pathology, and microbiology, primarily serving Andhra Pradesh's coastal regions. The company is debt-free and has been profitable for several years, demonstrating resilience in a competitive healthcare market. Dolphin Medical Services expanded its operations to include Dolphin Nethralaya, an eye care center offering advanced laser and research facilities. The company has diversified into IT, biotechnology, and herbal sectors, indicating strategic attempts at broadening its business scope.
Over the past 52 weeks, DOLPHMED has traded between a low of ₹0.00 and a high of ₹0.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
DOLPHMED has a market capitalization of approximately N/A. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
DOLPHMED’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of N/A Cr, DOLPHMED is classified as a N/A stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
DOLPHMED operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of DOLPHMED is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Earnings approval
Dolphin Medical Services scheduled a Board meeting on 16 May 2026 to consider and approve the audited financial results for the fourth quarter and financial year ended 31 March 2026.
Board Meeting Notice
Dolphin Medical Services will hold a Board meeting on 16 May 2026 to consider and approve the audited financial results for the quarter and financial year ended 31 March 2026.
Dolphin Medical Services Limited, founded in 1992, specializes in comprehensive diagnostic services, including radiology, pathology, and microbiology, primarily serving Andhra Pradesh's coastal regions.
The company is debt-free and has been profitable for several years, demonstrating resilience in a competitive healthcare market.
Dolphin Medical Services expanded its operations to include Dolphin Nethralaya, an eye care center offering advanced laser and research facilities.
The company has diversified into IT, biotechnology, and herbal sectors, indicating strategic attempts at broadening its business scope.
Bearish
0
Neutral
14
Bullish
0
Bearish
0
Neutral
46
Bullish
0
Bearish
0
Neutral
32
Bullish
0
